Adaptimmune Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADAP research report →
Range $1 – $4
Price Chart
About the company
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.
- CEO
- Adrian G. Rawcliffe
- IPO
- 2015
- Employees
- 506
- HQ
- Abingdon, GB
Get TickerSpark's AI analysis on ADAP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $75.16M
- P/E
- -0.08
- PEG
- 0.00
- P/S
- 1.07
- P/B
- 0.06
- EV/EBITDA
- 0.10
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1225.05%
- Net Margin
- 425.49%
- ROE
- 115.05%
- ROIC
- -157.59%
Latest fiscal year · YoY change
- Revenue
- $178.03M+195.3%
- Gross Profit
- $177.96M+252.9%
- Op Income
- $-68,760,000
- Net Income
- $-70,814,000+37.8%
- EPS
- $-0.28+50.4%
- OCF Growth
- +48.0%
- FCF Growth
- +47.9%
- 52W High
- $0.86
- 52W Low
- $0.02
- 50D MA
- $0.10
- 200D MA
- $0.26
- Beta
- 2.49
- RSI (14)
- 38
- Avg Volume
- 110.64M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BiomX said its BX004 CF program advanced despite a U.S. clinical hold tied to a nebulizer device, while FDA feedback on BX011 in diabetic foot infection strengthened the company’s regulatory path.· November 12, 2025
- BX004 Phase IIb dosed its first patient, but the U.S. trial sites were then put on FDA clinical hold over the third-party nebulizer device, not BX004 itself.
- Management said it submitted the requested nebulizer data, expects FDA feedback imminently, and still targets BX004 data in Q1 2026.
- FDA gave written feedback in October on BX004, outlining potential Phase III development paths and suggesting ways to enrich the patient population.
- BiomX received positive FDA feedback on BX011 for diabetic foot infection, with no additional nonclinical studies requested and CMC comments described as aligned with the company’s manufacturing approach.
- Cash remains limited at $8.1 million, and management said that is enough to fund operations only into the first quarter of 2026.
BiomX reported cash and restricted cash of $8.1 million as of September 30, 2025, down from $18 million at December 31, 2024. Third-quarter 2025 R&D expense was $6.1 million versus $7.3 million a year earlier, and G&A expense was $2.4 million versus $3.2 million. Net loss was $9.2 million in Q3 2025 compared with net income of $9.6 million in Q3 2024, with the year-over-year change mainly due to the fair value of warrants issued in the March 2024 financing. Net cash used in operating activities was $22 million for the first nine months of 2025 versus $30.7 million in the same period of 2024. Management said cash, cash equivalents and restricted cash are sufficient to fund operations into the first quarter of 2026. No revenue or EPS figure was stated on the call.
Jonathan Solomon framed the quarter as a period of regulatory progress and clinical execution, even with the setback of the U.S. clinical hold on BX004. He emphasized that the hold was technical and limited to the nebulizer device, while the FDA gave no concern about BX004 itself, and he said the company expects feedback imminently. He was notably constructive on both BX004 and BX011, describing FDA feedback as supportive and pointing to a clearer development path for each program, while stressing that financing and partnerships will matter for next steps.
Marina Wolfson focused on liquidity and expense trends. She said cash and restricted cash were $8.1 million at September 30, 2025 versus $18 million at year-end 2024, and that this is expected to fund operations into Q1 2026. She also cited Q3 R&D of $6.1 million, down from $7.3 million, and G&A of $2.4 million, down from $3.2 million, with lower salary, rent, legal and professional costs partly offset by depreciation and reduced grant funding. Net cash used in operating activities improved to $22 million for the first nine months of 2025 from $30.7 million a year earlier.
Analysts focused on the implications of FDA feedback for BX011 in DFI and on the BX004 clinical hold. Management said the DHA appears willing to support a commercial-first path in diabetic foot infection before later expanding to combat wounds, and that FDA feedback did not request extra animal or skin-penetration studies. For BX004, Solomon said the hold appears technical and limited to the nebulizer, with no FDA concern about the phage therapy itself, and he suggested the agency’s comments could support patient enrichment strategies such as non-CFTR-modulator patients or more frequent exacerbators. He also said the Phase III path is still rough at this stage and depends on Phase IIb results, financing, and possible partnerships.
The call presented two programs with clearer regulatory paths than before: BX011 got constructive FDA feedback, and BX004 received guidance on potential Phase III design plus a statement of unmet need in CF. Management also said the BX004 hold is device-related rather than drug-related, the European trial continues, and Q1 2026 data remain on track. If the hold is lifted and the readout is positive, management sees potential for a more focused development path and possible partnership interest.
The company has limited cash, with only $8.1 million on hand and a stated runway into Q1 2026, so financing remains a major constraint. BX004 enrollment in the U.S. is paused by the FDA hold, and the call did not provide a firm timeline for lifting it. BX011 still depends on securing resources and working through the next study design with the DHA, so both programs remain contingent on execution and funding.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.9%
- Shares Outstanding
- 258.27M
- Float Shares
- 255.41M
of shares held by institutions
57 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 193.76K | ▼ 95.93K |
| Lindbrook Capital, LLC | 4.61K | 0 |
| Sandy Spring Bank | 1.05K | 0 |
| Carmichael Hill & Associates, Inc. | 525 | 0 |
Our ADAP coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ADAP?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
businesswire.com · Jun 29
Adaptimmune Announces Changes to Board and Executive Leadership Team
newsfilecorp.com · Nov 17
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
businesswire.com · Oct 21
Adaptimmune Announces Delisting from Nasdaq
newsfilecorp.com · Oct 20
Adaptimmune Reports Q2 Financial Results and Provides Business Update
newsfilecorp.com · Aug 13
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
newsfilecorp.com · Jul 28
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
seekingalpha.com · May 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
